XFRA CAPITAL ADJUSTMENT INFORMATION

Realtime	Geld	Brief	Zeit
	0,153	0,159	07:39
	0,132	0,190	07:41

Realtime

Geld

Brief

Zeit

0,153

0,159

07:39

0,132

0,190

07:41

XFRA CAPITAL ADJUSTMENT INFORMATION - 15.04.2025

Das Instrument K3E NL0000852531 KENDRION N.V. EO 2 EQUITY wird cum Kapitalmassnahme gehandelt am 15.04.2025 und ex Kapitalmassnahme am 16.04.2025
The instrument K3E NL0000852531 KENDRION N.V. EO 2 EQUITY is traded cum capital adjustment on 15.04.2025 and ex capital adjustment on 16.04.2025

Das Instrument OIC NL0010558797 OCI N.V. EO 0,02 EQUITY wird ex Kapitalmassnahme gehandelt am 15.04.2025
The instrument OIC NL0010558797 OCI N.V. EO 0,02 EQUITY is traded ex capital adjustment on 15.04.2025

Das Instrument R9Q AU000000RCE5 RECCE PHARMACEUTICALS LTD EQUITY wird ex Kapitalmassnahme gehandelt am 15.04.2025
The instrument R9Q AU000000RCE5 RECCE PHARMACEUTICALS LTD EQUITY is traded ex capital adjustment on 15.04.2025

Das Instrument GET FR0000130692 CHARGEURS INH. EO 12,- EQUITY wird ex Kapitalmassnahme gehandelt am 15.04.2025
The instrument GET FR0000130692 CHARGEURS INH. EO 12,- EQUITY is traded ex capital adjustment on 15.04.2025

Zeit	Aktuelle Nachrichten
16.04.	Chargeurs PCC appoints key executives in strategic positions
15.04.	COMPAGNIE CHARGEURS INVEST: Voting rights monthly statement as of March 31st, 2025
15.04.	XFRA CAPITAL ADJUSTMENT INFORMATION - 15.04.2025	Das Instrument K3E NL0000852531 KENDRION N.V. EO 2 EQUITY wird cum Kapitalmassnahme gehandelt am 15.04.2025 und ex Kapitalmassnahme am 16.04.2025 The instrument K3E NL0000852531 KENDRION N.V. EO 2 EQUITY... ► Artikel lesen
09.04.	CHARGEURS: Minutes of the Combined General Meeting held on April 9, 2025
09.04.	CHARGEURS: Description of the 2025-2026 Share Buyback Program

Zeit

Aktuelle Nachrichten

16.04.

Chargeurs PCC appoints key executives in strategic positions

15.04.

COMPAGNIE CHARGEURS INVEST: Voting rights monthly statement as of March 31st, 2025

15.04.

XFRA CAPITAL ADJUSTMENT INFORMATION - 15.04.2025

09.04.

CHARGEURS: Minutes of the Combined General Meeting held on April 9, 2025

09.04.

CHARGEURS: Description of the 2025-2026 Share Buyback Program

Zeit	Aktuelle Nachrichten
15.04.	XFRA CAPITAL ADJUSTMENT INFORMATION - 15.04.2025	Das Instrument K3E NL0000852531 KENDRION N.V. EO 2 EQUITY wird cum Kapitalmassnahme gehandelt am 15.04.2025 und ex Kapitalmassnahme am 16.04.2025 The instrument K3E NL0000852531 KENDRION N.V. EO 2 EQUITY... ► Artikel lesen
04.04.	Kendrion N.V.: Statement on import tariffs	Dear Stakeholders, As we navigate through yet another era of global uncertainty, we must recognize the challenges ahead. The world seems to be heading into a global trade war, following a series... ► Artikel lesen
28.02.	Kendrion N.V.: Q4 and Full Year results 2024 - Kendrion ready to deliver as pure-play Industrial company, prioritizing profitability	- FY 2024 revenue from continued operations reached EUR 301.5 million, a 2% decline compared to FY 2023 (EUR 309.0 million) - Q4 2024 revenue from continued operations increased by 8% to EUR... ► Artikel lesen
12.11.24	Kendrion N.V.: Q3 results 2024: Kendrion posts stable performance of continuing operations	- Q3 2024 revenue from continuing operations was EUR 72.7 million, slightly up from EUR 72.1 million in Q3 2023. - Normalized EBITDA from continued operations of EUR 8.9 million (Q3 2023: EUR... ► Artikel lesen

Zeit

Aktuelle Nachrichten

15.04.

XFRA CAPITAL ADJUSTMENT INFORMATION - 15.04.2025

04.04.

Kendrion N.V.: Statement on import tariffs

Dear Stakeholders, As we navigate through yet another era of global uncertainty, we must recognize the challenges ahead. The world seems to be heading into a global trade war, following a series...
► Artikel lesen

28.02.

Kendrion N.V.: Q4 and Full Year results 2024 - Kendrion ready to deliver as pure-play Industrial company, prioritizing profitability

- FY 2024 revenue from continued operations reached EUR 301.5 million, a 2% decline compared to FY 2023 (EUR 309.0 million) - Q4 2024 revenue from continued operations increased by 8% to EUR...
► Artikel lesen

12.11.24

Kendrion N.V.: Q3 results 2024: Kendrion posts stable performance of continuing operations

- Q3 2024 revenue from continuing operations was EUR 72.7 million, slightly up from EUR 72.1 million in Q3 2023. - Normalized EBITDA from continued operations of EUR 8.9 million (Q3 2023: EUR...
► Artikel lesen

Zeit	Aktuelle Nachrichten
16.04.	OCI Global Confirms Euro Equivalent Details For Q2 2025 Extraordinary Distribution	AMSTERDAM, April 16, 2025 /PRNewswire/ -- OCI Global (Euronext: OCI) ("OCI" or the "Company") today confirms that further to its announcement to pay an extraordinary cash distribution of USD... ► Artikel lesen
15.04.	Dividendenbekanntmachungen (15.04.2025)	Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) A-MARK PRECIOUS METALS INC US00181T1079 0,2 USD 0,1761 EUR ABBOTT LABORATORIES US0028241000 0,59 USD 0,5195 EUR ABBOTT LABORATORIES US0028241000 0... ► Artikel lesen
15.04.	XFRA CAPITAL ADJUSTMENT INFORMATION - 15.04.2025	Das Instrument K3E NL0000852531 KENDRION N.V. EO 2 EQUITY wird cum Kapitalmassnahme gehandelt am 15.04.2025 und ex Kapitalmassnahme am 16.04.2025 The instrument K3E NL0000852531 KENDRION N.V. EO 2 EQUITY... ► Artikel lesen
08.04.	OCI Global Announces Agreement with Bondholders	AMSTERDAM, April 8, 2025 /PRNewswire/ -- OCI Global (Euronext: OCI) a leading global producer and distributor of hydrogen products today announced that it has reached a support agreement... ► Artikel lesen
02.04.	Moody's downgrades OCI's credit rating, keeps it under review for further downgrades

Zeit

Aktuelle Nachrichten

16.04.

OCI Global Confirms Euro Equivalent Details For Q2 2025 Extraordinary Distribution

AMSTERDAM, April 16, 2025 /PRNewswire/ -- OCI Global (Euronext: OCI) ("OCI" or the "Company") today confirms that further to its announcement to pay an extraordinary cash distribution of USD...
► Artikel lesen

15.04.

Dividendenbekanntmachungen (15.04.2025)

Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) A-MARK PRECIOUS METALS INC US00181T1079 0,2 USD 0,1761 EUR ABBOTT LABORATORIES US0028241000 0,59 USD 0,5195 EUR ABBOTT LABORATORIES US0028241000 0...
► Artikel lesen

15.04.

XFRA CAPITAL ADJUSTMENT INFORMATION - 15.04.2025

08.04.

OCI Global Announces Agreement with Bondholders

AMSTERDAM, April 8, 2025 /PRNewswire/ -- OCI Global (Euronext: OCI) a leading global producer and distributor of hydrogen products today announced that it has reached a support agreement...
► Artikel lesen

02.04.

Moody's downgrades OCI's credit rating, keeps it under review for further downgrades

Zeit	Aktuelle Nachrichten
Mi	RECCE PHARMACEUTICALS LTD: Ceasing to be a substantial holder from MQG
Mi	RECCE PHARMACEUTICALS LTD: Investor Webinar Recording Available
Di	Innovatives Gel von Recce Pharmaceuticals bietet neue Hoffnung für diabetische Patienten
Di	Revitalisierte Therapieoptionen: Recce Pharmaceuticals erhält erweiterte Zulassung für Diabetesbehandlungen.
Di	Recce Raises $4M in Funding

Zeit

Aktuelle Nachrichten

RECCE PHARMACEUTICALS LTD: Ceasing to be a substantial holder from MQG

RECCE PHARMACEUTICALS LTD: Investor Webinar Recording Available

Innovatives Gel von Recce Pharmaceuticals bietet neue Hoffnung für diabetische Patienten

Revitalisierte Therapieoptionen: Recce Pharmaceuticals erhält erweiterte Zulassung für Diabetesbehandlungen.

Recce Raises $4M in Funding